RCT Targeting Cognition in Early Alzheimer's Disease by Improving Sleep With Trazodone (REST)
Overview
- Phase
- Phase 2
- Intervention
- Placebo
- Conditions
- AMCI - Amnestic Mild Cognitive Impairment
- Sponsor
- Johns Hopkins University
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- Change in Slow Wave Sleep (SWS) duration between the treatment arms
- Status
- Recruiting
- Last Updated
- 7 months ago
Overview
Brief Summary
To investigate the effect of trazodone on sleep, hippocampal-dependent memory and hippocampal excitability. The investigators hypothesize that trazodone will improve total sleep time and proportion of time in Slow Wave Sleep (SWS).
Detailed Description
The REST trial is a randomized, placebo-controlled, double-blind crossover study of trazodone (50 mg at bedtime) in participants with Amnestic Mild Cognitive impairment (aMCI) and sleep complaints. The investigators will randomize 100 subjects and administer trazodone and placebo for 4 weeks each with a 4-week washout period in between. A 4-week washout period is more than sufficient due to trazodone's elimination half-life of 10-12 hours. The crossover design will facilitate recruitment and enable the use of the subjects as a control without requiring a parallel placebo arm.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Mild Cognitive Impairment (MCI) as defined by Albert et al.2 including subjective memory complaint and/or objective evidence of memory problems;
- •Clinical Dementia Rating (CDR) of 0.5 with a Memory Box score of \>=0.5;
- •Evidence of sleep complaints with Pittsburgh Sleep Quality Index score of \>5 (a well-validated cutoff observed in \>40% of older persons);
- •Memory performance \> 1.5 Standard Deviation (SD) below age-and education-matched control subjects on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) List Recall;
- •Visual and auditory acuity adequate for neuropsychological testing;
- •Good general health with no disease expected to interfere with the study;
- •Able to have Magnetic Resonance Imaging (MRI) scan;
- •Availability of knowledgeable informant (KI)
Exclusion Criteria
- •Less than 55 years of age to reduce likelihood of including individuals with frontotemporal dementia or non-dementia MCI;
- •Too frail or medically unstable to undergo study procedures;
- •Prior diagnosis of Obstructive Sleep Apnea (OSA) or evidence of moderate-to-severe OSA on baseline Home Sleep Test (HST) as evidenced by an apnea/hypopnea index of \>15;
- •Cognitive complaints and deficits better explained by other medical/neurologic conditions;
- •Allergic to trazodone;
- •Taking sleep medications including trazodone;
- •Current substance abuse;
- •Current major depressive, manic, or acute psychotic episode;
- •Prior diagnosis of significant systemic illness or unstable medical condition which could lead to difficulty complying with the study protocol or represent alternate primary cause of memory problems beyond Alzheimer's Disease (AD) pathology:
- •Lack of available KI;
Arms & Interventions
Trazodone First
Trazodone (50 mg at bedtime) and then placebo after a 4-week washout period.
Intervention: Placebo
Trazodone First
Trazodone (50 mg at bedtime) and then placebo after a 4-week washout period.
Intervention: Trazodone
Placebo First
Placebo and then Trazodone (50 mg at bedtime) after a 4-week washout period.
Intervention: Trazodone
Placebo First
Placebo and then Trazodone (50 mg at bedtime) after a 4-week washout period.
Intervention: Placebo
Outcomes
Primary Outcomes
Change in Slow Wave Sleep (SWS) duration between the treatment arms
Time Frame: Baseline and End of study, up to 12 weeks
Comparison of means of SWS from baseline measured in minutes between trazodone and placebo arm.
Change in self reported sleep measure Epworth Sleepiness Score (ESS) between treatment arms
Time Frame: Baseline and End of study, up to 12 weeks
Comparison of means score for ESS from baseline between trazodone and placebo arm. A higher score means a worse outcome.
Change in total sleep duration between the treatment arms
Time Frame: Baseline and End of study, up to 12 weeks
Comparison of means of total sleep duration from baseline measured in minutes between trazodone and placebo arm.
Change in SWS intensity between the treatment arms
Time Frame: Baseline and End of study, up to 12 weeks
Comparison of means of SWS intensity measured from baseline in volts squared between trazodone and placebo arm.
Change in sleep onset latency between the treatment arms
Time Frame: Baseline and End of study, up to 12 weeks
Comparison of means of sleep onset latency from baseline measured in minutes between trazodone and placebo arm.
Change in sleep fragmentation between the treatment arms
Time Frame: Baseline and End of study, up to 12 weeks
Comparison of means of sleep fragmentation from baseline measured in minutes between trazodone and placebo arm.
Change in self reported sleep measure Pittsburgh Sleep Quality Index (PSQI) between treatment arms
Time Frame: Baseline and End of study, up to 12 weeks
Comparison of means score for PSQI from baseline between trazodone and placebo arm. A higher score means a worse outcome.
Secondary Outcomes
- Change in memory performance between treatment arms(Baseline and End of study, up to 12 weeks)
- Change in hippocampal activation on Function Magnetic Resonance Imaging (fMRI) measures during memory functioning between treatment arms(Baseline and End of study, up to 12 weeks)